<DOC>
	<DOCNO>NCT01014559</DOCNO>
	<brief_summary>The primary objective trial study efficacy oxycodone/naloxone prolong release tablet ( OXN PR ) , compare oxycodone prolong release tablet ( Oxy PR ) , reduction intensity opioid-induced constipation symptom patient treat cancer non-cancer pain .</brief_summary>
	<brief_title>Efficacy Oxycodone/Naloxone ( OXN ) , Versus Oxycodone ( OXY ) , Reduction Intensity Opioid-induced Constipation Pain Patients</brief_title>
	<detailed_description>Eligible patient document cancer non-cancer pain , either currently receive WHO step II opioid require initiation WHO step III opioid currently receive WHO step III opioid , opioid-related constipation define either KESS score ≥9 current use laxative ( ≥3 time per week ) , randomly assign receive either OXN PR Oxy PR . Randomisation stratify cause pain : cancer non-cancer . Any patient complete study wish receive OXN PR afterwards may enter optional open extension phase . During phase , patient receive OXN PR manage per usual practice center commercial OXN PR available France ( limit 1 year Day 28 ) . Adverse event assess visit .</detailed_description>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Naloxone</mesh_term>
	<mesh_term>Oxycodone</mesh_term>
	<criteria>Inclusion criterion 1 . Male female patient age 18 year old . 2 . With cancer pain noncancer pain chronic low back pain , osteoarthritis . 3 . Either currently receive WHO step II opioid require initiation WHO step III opioid ( due lack efficacy step II opioid ) expect last 28 day , currently receive WHO step III opioid expect last 28 day . 4 . Having opioidrelated constipation define either KESS score ≥ 9 current use laxative ( least 3 time per week ) . 5 . Able , opinion Investigator , comply study protocol . 6 . Women childbearing potential must negative urine pregnancy test result inclusion ( test supervision investigator ) use effective birth control method . Women nonchildbearing potential must postmenopausal surgically sterile ( hysterectomy and/or bilateral oophorectomy ) . 7 . Having receive oral write information study protocol sign write , inform consent participate . Exclusion criteria 1 . Pregnancy breastfeed . 2 . Known contraindication hypersensitivity oxycodone , naloxone , bisacodyl , chemically close substance , ingredient . 3 . Clinically significant impairment cardiovascular , respiratory , liver kidney function disease , determine medical history , clinical laboratory test , ECG result , physical examination , opinion Investigator may present risk upon exposure study medication . 4 . Known suspect unstable brain spinal cord metastasis may require change steroid treatment throughout duration study . 5 . Increased intracranial pressure . 6 . Evidence clinically significant gastrointestinal disease ( e.g. , paralytic ileus , peritoneal carcinosis ) , significant structural abnormality gastrointestinal tract ( e.g. , scar , obstruction etc ) either relate related underlying cancer disease progression . 7 . Rheumatoid arthritis , comedication may impact study result , especially comedication stable within study . 8 . Surgery complete prior start study , plan surgery study would influence pain bowel function study preclude completion study . 9 . Cyclic chemotherapy two week inclusion plan study show past influence bowel function . Patients first cycle chemotherapy 2 week inclusion visit study include study . 10 . Radiotherapy , investigator opinion , would influence bowel function pain study . 11 . Treatment opioid receptor antagonist month precede inclusion . 12 . History alcohol , opioid drug abuse . 13 . Current treatment another psychoactive drug , opinion Investigator , may present risk associate opioid . 14 . Any somatic psychic condition , opinion Investigator , may compromise ability patient understand comply study protocol provide inform consent participate . 15 . Patient participate clinical research involve new chemical entity experimental drug within 30 day study entry . Concurrent enrolment another clinical trial permit unless sole purpose trial time OXN3505 inclusion visit longterm followup/survival data .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Constipation</keyword>
	<keyword>Oxycodone</keyword>
	<keyword>Oxycodone hydrochloride</keyword>
	<keyword>Naloxone hydrochloride</keyword>
	<keyword>Naloxone</keyword>
</DOC>